Olorofim (F901318) is an experimental antifungal drug being developed for invasive mold infections.
[1][2] If approved it would be a first-in-class medication (for the orotomide class).
In 2023, the FDA decided not to approve the drug and to request more data about the safety of the drug.
[3] Olorofim does not inhibit growth of Candida species.
[2]